Global partnerships Leverage existing collaborations with Emblem Corp in Canada and the joint venture with Queensland Bauxite to accelerate market entry in Australia and Asia, focusing on regulated markets for medical hard pill cannabinoid formulations.

Regulatory momentum Two products have already secured NPN numbers from Health Canada, indicating a path to broader Canadian commercialization and potential parallel approvals or listings in other regulated markets.

Diversified delivery Portfolio includes extended, immediate, modified, and bi-layered hard pills delivering precise cannabinoid and terpenoid blends, offering a compelling value proposition for clinics and pharmacists seeking accurate dosing and discreet administration.

Strategic leadership Recent leadership appointments and advisory inputs position Canntab to pursue rapid commercialization and enterprise sales, with a focus on expanding into health and wellness channels and Indigenous health initiatives.

Near-term traction Active online platform and eCommerce presence plus interim CEO transition signal organizational readiness for direct-to-consumer or point-of-care channels, enabling sales outreach to medical practitioners, pharmacies, and wellness retailers.